Rationale of use and effectiveness of Longidaza in patients with chronic prostatitis


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Introduction. Chronic inflammation of the prostate leads to the formation of excess fibrous connective tissue, which hinders patients’ recovery and aggravates the symptoms. Aim. This study aimed to confirm the correlation between inflammation and prostatic fibrosis and the abnormalities of urodynamic and microcirculation in the prostate gland in humans, and the possibility of increasing the effectiveness of treatment of patients with chronic nonbacterial prostatitis using antisclerotic therapy. Material and methods. The study was carried out in two stages. At the first stage, pathomorphological findings, uroflowmetry data and degree of microcirculation disturbance were studied in 18 patients with chronic prostatitis who underwent prostate biopsy. At the second stage, an open prospective randomized comparative study was conducted. Two groups of patients with chronic nonbacterial prostatitis with signs of inflammation were formed. A control group (n=29) received standard treatment, rectal 0.5 methyluracil suppositories three times per week, 20 suppositories per course. In addition to the standard treatment, the patients of the study group (n=31) were administered Longidaza 3000 IU rectal suppositories also three times a week, 20 suppositories per course. Results. Prostatic fibrosis worsens microcirculation by one and half times and statistically significantly negatively affects urodynamic. Using Longidaza resulted in neutralizing the negative consequences of the formation of excess fibrous connective tissue. Overall, an excellent and good effect was achieved in 21 (67.7%) and 9 (29.1%) patients of the study group, respectively; only in one case (3.2%) there was no effect. In the control group, an excellent and good effect was achieved in 14 (48.3%) and 11 (37.9%) patients, respectively; in 4 patients (13.8%) the treatment was considered of low effectiveness. Conclusions. Prevention of the fibrous connective tissue formation and regression of the fibrosis are pathogenetically valid. Anti-sclerotic enzyme therapy with Longidaza in the form of rectal suppositories results in a significant improvement in the symptoms of prostatitis, an increase in the maximum urinary flow rate and an improvement in the microcirculation of the prostate.

Full Text

Restricted Access

About the authors

E. V Kulchavenya

Novosibirsk Tuberculosis Research Institute of Minzdrav of Russia; Novosibirsk State Medical University of Minzdrav of Russia

Email: urotub@yandex.ru
Dr.Med.Sci., Prof., Principal Research Fellow at TB Research Institute, Prof. at Department of Tuberculosis of NSMU

O. P Shvetsova

Novosibirsk Tuberculosis Research Institute of Minzdrav of Russia

Email: urotub@yandex.ru
Head of the Pathomorphological Laboratory

A. A Breusov

Medical Center Biovar

Ph.D., Director

References

  1. Resolution of chronic bacterial-induced prostatic inflammation reverses established fibrosis. Prostate. 2015;75(1):23-32.
  2. Nickel J.C., Roehrborn C.G., O’Leary M.P., Bostwick D.G., Somerville M.C., Rittmaster R.S. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379-1384.
  3. Roehrborn C.G. Definition of at-risk patients: baseline variables. BJU Int. 2006;97(2):7-11.
  4. Bercovich E., Barabino G., Pirozzi-Farina F., Deriu M. A multivariate analysis of lower urinary tract ageing and urinary symptoms: the role of fibrosis. Arch Ital Urol Androl. 1999;71:287-292.
  5. Ma J., Gharaee-Kermani M., Kunju L., Hollingsworth J.M., Adler J., Arruda E.M., Macoska J.A. Prostatic fibrosis is associated with lower urinary tract symptoms. J. Urol. 2012;188:1375-1381.
  6. Кудрявцев Ю.В., Чумаков А.М. Морфологические изменения в предстательной железе при хроническом простатите. Материалы конференции «Современные аспекты диагностики и лечения хронического простатита». Курск. 2000;81-82
  7. Wight T.N., Potter-Perigo S. The extracellular matrix: an active or passive player in fibrosis? Am J. Physiol Gastrointest Liver Physiol. 2011;301:950-955.
  8. Gordon M.K., Hahn R.A. Collagens. Cell Tissue Res. 2010;339:247-257.
  9. Frantz C., Stewart K.M., Weaver V.M. The extracellular matrix at a glance. J. Cell Sci. 2010;123:4195-4200.
  10. Kadler K.E., Baldock C., Bella J., Boot-Handford R.P. Collagens at a glance.J. Cell Sci. 2007;120:1955-1958.
  11. Rodes J. Textbook of hepatology from basic science to clinical practice. 3rd ed. Malden, 2007; Mass.: Blackwell.
  12. Thickett D.R., Poole A.R., Millar A.B. The balance between collagen synthesis and degradation in diffuse lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2001;18:27-33.
  13. Armstrong L., Thickett D.R., Mansell J.P., Ionescu M., Hoyle E., Billinghurst R.C., Poole A.R., Millar A.B. Changes in collagen turnover in early acute respiratory distress syndrome. Am J. Respir Crit Care Med. 1999;160:1910-1915.
  14. Garci'a-Bolao I., Lopez B., Macias A., Gavira J.J., Azcârate P., Diez J. Impact of collagen type I. turnover on the long-term response to cardiac resynchronization therapy. Eur Heart J. 2008;29: 898-906.
  15. Selman M., Montano M., Ramos C., Chapela R. Concentration, biosynthesis and degradation of collagen in idiopathic pulmonary fibrosis. Thorax. 1986;41:355-359.
  16. Кульчавеня Е.В., Краснов В.А., Мордык А.В. Альманах внелёгочного туберкулёза. - Новосибирск: Сибпринт. 2015;247. илл. ISBN 978-5-94301-579-3
  17. Bushman W. Prostatic inflammation induces fibrosis in a mouse model of chronic bacterial infection. PLoS One. 2014;9(6):100770. Doi: 10.1371/ journal.pone.0100770. eCollection 2014.
  18. Cantiello F., Cicione A., Salonia A., Autorino R., Tucci L., Madeo I., Damiano R. Periurethral fibrosis secondary to prostatic inflammation causing lower urinary tract symptoms: a prospective cohort study. Urology. 2013;81(5):1018-1023. doi: 10.1016/j.urology.2013.01.053.
  19. Hu Y., Niu X., Wang G., Huang J., Liu M., Peng B. Chronic prostatitis/ chronic pelvic pain syndrome impairs erectile function through increased endothelial dysfunction, oxidative stress, apoptosis, and corporal fibrosis in a rat model. Andrology. 2016;4(6):1209-1216. Doi: 10.1111/ andr.12273. Epub 2016 Aug 27.
  20. Горбунова Е.Н., Давыдова Д.А., Крупин В.Н. Хроническое воспаление и фиброз как факторы риска простатических интраэпиетлиальных неоплазий и рака предстательной железы. Современные технологии в медицине. 2011;1:79-83
  21. Неймарк А.И., Киптилов А.В., Лапий Г.А. Клинические и патоморфологические особенности хронического простатита у рабочих химического производства. Урология. 2015;3:68-73
  22. Зайцев А.В., Пушкарь Д.Ю., Ходырева Л.А., Дударева А.А. Хронический бактериальный простатит, расстройства мочеиспускания у мужчин и фиброз предстательной железы. Урология. 2016;4:114-120
  23. Пушкарь Д.Ю., Зайцев А.В., Сегал А.С. Лонгидаза в терапии хронического простатита. Иммунология. 2006;27(2):119-121
  24. Пушкарь Д.Ю., Зайцев A.B., Сегал A.C. Лонгидаза в лечении хронического простатита. Урология. 2006;6:26-28
  25. Ходырева Л.А., Дударева А.А., Карпов В.К. Лонгидаза в комплексной терапии хронического простатита. Эффективная фармакотерапия. 2014;32:10-15
  26. Авдошин В.П., Андрюхин М.И., Пульбере С.А., Макаров О.В., Михайликов Т.Г. Оценка клинической эффективности препарата Лонгидаза в комплексном лечении больных хроническим простатитом. Эффективная фармакотерапия. 2012;43:22-25
  27. Авдошин В.П., Андрюхин М.И., Михайликов Т.Г. Опыт применения ферментной терапии в комплексном лечении хронического простатита. Consilium medicum. 2008;4:114-117
  28. Авдошин В.П., Михайликов Т.Г., Андрюхин М.И., Ольшанская Е.В., Пульбере С.А. Оценка эффективности лечения больных хроническим простатитом препаратом лонгидаза 3000 М.Е. Клиническая фармакология и терапия. 2010; 19(4) : 93-97

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies